CRBP logo

CRBP
Corbus Pharmaceuticals Holdings Inc

21,408
Mkt Cap
$204.36M
Volume
747.00
52W High
$20.56
52W Low
$6.72
PE Ratio
-1.90
CRBP Fundamentals
Price
$11.03
Prev Close
$11.98
Open
$11.93
50D MA
$9.95
Beta
1.19
Avg. Volume
268,308.35
EPS (Annual)
-$5.90
P/B
1.55
Rev/Employee
$0.00
$53.90
Loading...
Loading...
News
all
press releases
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Rating Upgraded by Guggenheim
Guggenheim upgraded Corbus Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday...
MarketBeat·17d ago
News Placeholder
More News
News Placeholder
Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday
Corbus Pharmaceuticals (NASDAQ:CRBP) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-corbus-pharmaceuticals-holdings-inc-stock...
MarketBeat·20d ago
News Placeholder
Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Crosses Above Fifty Day Moving Average - Should You Sell?
Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Cross Above 50-Day Moving Average - Should You Sell...
MarketBeat·23d ago
News Placeholder
Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded by Wall Street Zen to "Sell" Rating
Wall Street Zen raised shares of Corbus Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday...
MarketBeat·23d ago
News Placeholder
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten research firms that are presently covering the...
MarketBeat·1mo ago
News Placeholder
Corbus Pharmaceuticals Holdings, Inc. $CRBP Stock Holdings Lifted by Aberdeen Group plc
Aberdeen Group plc lifted its position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 602.2% during the 4th quarter, according to the company in its most recent disclosure...
MarketBeat·1mo ago
News Placeholder
Corbus Pharma Aligns With FDA On Registration Path For CRB-701 In HNSCC And Cervical Cancer
(RTTNews) - Corbus Pharmaceuticals Holdings, Inc. (CRBP), a clinical-stage company, Tuesday announced that it broadly aligned with the FDA on the registration path for CRB-701, a highly stable Nectin-4 targeting ADC, in head and neck squamous cell carcinoma (HNSCC) and cervical c...
Nasdaq News: Markets·1mo ago
News Placeholder
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Crosses Above 50-Day Moving Average - Time to Sell?
Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Pass Above 50 Day Moving Average - What's Next...
MarketBeat·2mo ago
News Placeholder
HC Wainwright Issues Negative Forecast for CRBP Earnings
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Research analysts at HC Wainwright dropped their Q1 2026 earnings estimates for shares of Corbus Pharmaceuticals in a research...
MarketBeat·2mo ago
News Placeholder
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%
The mean of analysts' price targets for Corbus Pharmaceuticals (CRBP) points to a 318.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·2mo ago
<
1
2
...
>

Latest CRBP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.